Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2
Dittmar, M.; Lee, J. S.; Whig, K.; Segrist, E.; Li, M.; Jurado, K.; Samby, K.; Ramage, H.; Schultz, D.; Cherry, S.
Show abstract
There are an urgent need for antivirals to treat the newly emerged SARS-CoV-2. To identify new candidates we screened a repurposing library of ~3,000 drugs. Screening in Vero cells found few antivirals, while screening in human Huh7.5 cells validated 23 diverse antiviral drugs. Extending our studies to lung epithelial cells, we found that there are major differences in drug sensitivity and entry pathways used by SARS-CoV-2 in these cells. Entry in lung epithelial Calu-3 cells is pH-independent and requires TMPRSS2, while entry in Vero and Huh7.5 cells requires low pH and triggering by acid-dependent endosomal proteases. Moreover, we found 9 drugs are antiviral in lung cells, 7 of which have been tested in humans, and 3 are FDA approved including Cyclosporine which we found is targeting Cyclophilin rather than Calcineurin for its antiviral activity. These antivirals reveal essential host targets and have the potential for rapid clinical implementation.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral replication-transcription complex in culture cells 96%
- Inhibitors of anti-apoptotic Bcl-2 family proteins exhibit potent and broad-spectrum anti-mammarenavirus activity via cell cycle arrest at G0/G1 phase 95%
- Identification of an antiretroviral small molecule that appears to be a host-targeting inhibitor of HIV-1 assembly 95%
Similar papers in this journal
- The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication 96%
- JIB-04 has broad-spectrum antiviral activity and inhibits SARS-CoV-2 replication and coronavirus pathogenesis 96%
- Evolution of antiviral resistance captures a transient interdomain functional interaction between chikungunya virus envelope glycoproteins 94%
Similar papers in this journal
Similar papers in this journal
- Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection 95%
- Development of an improved inhibitor of Lats kinases to promote regeneration of mammalian organs 93%
- Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth 93%
Similar papers in this journal
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 95%
- Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo 94%
- Targeting the host transcription factor HSF1 prevents human cytomegalovirus replication in vitro and in vivo 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.